Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Venetoclax and Obinutuzumab in CLL

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

July 30th 2020

Second-Generation BTK Inhibitors in CLL

July 30th 2020

Therapies in the Pipeline for Frontline CLL

July 30th 2020

Telemedicine for Patients With CLL

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

July 30th 2020

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020

Selecting First-Line Therapy for CLL

July 30th 2020

Advances in Frontline Therapy for CLL

July 30th 2020

Impact of COVID-19 on Management of CLL

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

Updated Data Confirm Long-Term Benefit With Tafasitamab/Lenalidomide in Relapsed/Refractory DLBCL

July 24th 2020

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Ghosh on Safety Results From the Phase 2 PILOT Trial in Non-Hodgkin Lymphoma

July 23rd 2020

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Selinexor Shows Meaningful, Durable Responses Linked With Improved OS in DLBCL

July 23rd 2020

Single-agent selinexor was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy.